Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0791
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2614
    -0.0008 (-0.06%)
     
  • USD/JPY

    151.3260
    -0.0460 (-0.03%)
     
  • Bitcoin USD

    70,243.94
    -315.41 (-0.45%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Orphan drug status granted for GMI-1070 in Europe

GlycoMimetics announced that the European Medicines Agency has granted orphan drug designation for GMI-1070 for the treatment of vaso-occlusive crisis in patients with sickle cell disease. GMI-1070, which has previously received both orphan drug and fast track status for VOC from the U.S. Food & Drug Administration, is being developed in partnership with Pfizer. Pfizer is responsible for the next steps of clinical development for GMI-1070.

Advertisement